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Abstract
Background: We examined the effectiveness and tolerability of transdermal buprenorphine (TDB) treatment in
real-world setting in Asian patients with musculoskeletal pain.
Methods: This was an open-label study conducted in Hong Kong, Korea, and the Philippines between June 2013
and April 2015. Eligible patients fulfilled the following criteria: 18 to 80 years of age; clinical diagnosis of
osteoarthritis, rheumatoid arthritis, low back pain, or joint/muscle pain; chronic non-malignant pain of moderate
to severe intensity (Box-Scale-11 [BS-11] pain score ≥ 4), not adequately controlled with non-opioid analgesics and
requiring an opioid for adequate analgesia; and no prior history of opioid treatment. Patients started with a 5 μg/h
buprenorphine patch and were titrated as necessary to a maximum of 40 μg/h over a 6-week period to achieve
optimal pain control. Patients continued treatment with the titrated dose for 11 weeks. The primary efficacy
endpoint was the change in BS-11 pain scores. Other endpoints included patients’ sleep quality and quality of
life as assessed by the 8-item Global Sleep Quality Assessment Scale (GSQA) questionnaire and the EuroQol Group
5-Dimension Self-Report Questionnaire-3 Level version (EQ-5D-3 L), respectively. Tolerability was assessed by
collecting adverse events.
Results: A total of 114 eligible patients were included in the analysis. The mean BS-11 score at baseline was 6.2
(SD 1.6). Following initiation of TDB, there was a statistically significant improvement in BS-11 score from baseline
to visit 3 (least squares [LS] mean change: -2.27 [95% CI -2.66 to −1.87]), which was maintained till the end of the
study (visit 7) (LS mean change: −2.64 [95% -3.05 to −2.23]) (p < 0.0001 for both). The proportion of patients who
rated sleep quality as ‘good’ increased from 14.0% at baseline to 26.9% at visit 6. By visit 6, the mean EQ VAS score
increased by 7.7 units (SD 17.9). There were also significant improvements in patients’ levels of functioning for all
EQ-5D-3 L dimensions from baseline at visit 6 (p < 0.05 for all). Seventy-eight percent of patients reported TEAEs
and 22.8% of patients discontinued due to TEAEs. TEAEs were generally mild to moderate in intensity (96.5%).
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Conclusions: TDB provides effective pain relief with an acceptable tolerability profile over the 11-week treatment
period in Asian patients with chronic musculoskeletal pain. More studies are needed to examine the long-term
efficacy and safety of TBD treatment in this patient population.
Trial registration: ClinicalTrials.gov NCT01961271. Registered 7 October 2013 (retrospectively registered; first patient
was enrolled on 28 June 2013 and last patient last visit date was 26 Apr 2015).
Keywords: Transdermal buprenorphine, Asian, Chronic non-malignant pain, Musculoskeletal, Pain score, Quality of
life, Sleep quality, Effectiveness, Tolerability
Background
Musculoskeletal disorders are among the most common
causes of chronic non-malignant pain in adults. Unrelieved
pain has significant physiological and psychological impact
on patients, affecting their daily quality of life as well as
increasing their financial burden [1]. A comprehensive ap-
proach encompassing pharmacological and physical therap-
ies, tailored to the individual needs of patients, is needed to
reduce pain, promote functional recovery, and improve
overall quality of life [2].
Systematic reviews examining evidence on the use of
opioid analgesics for the treatment of chronic non-
malignant pain suggested these are efficacious in treating
pain of various etiologies [3, 4]. However, opioid treatment
is associated with typical opioid-induced side effects and
potential risk of opioid abuse which can lead to addiction,
severe respiratory depression, or even death [3–5]. Guide-
lines recommend the use of opioid analgesics for the treat-
ment chronic non-malignant pain in patients whose pain
persists despite optimized non-opioid treatment. They
stress the importance of careful selection of patients who
are not at risk of opioid abuse or diversion and ongoing
monitoring, together with balancing the goal of achieving
pain relief with the risks for opioid abuse or addiction
when prescribing treatment [6–8]. Opioid formulations
with extended-release (ER) and tamper-resistant proper-
ties offer the advantage of achieving analgesia while
minimizing risks for opioid abuse or addiction [9–11].
Unlike immediate-release (IR) formulations, ER formu-
lations provide relatively consistent and prolonged
plasma drug levels with fewer peak-to-trough fluctua-
tions and lower peak plasma concentration. This results
in prolonged analgesia with less frequent dosing and re-
duced risks of opioid overdose, respiratory depression,
and opioid addiction. In addition, the longer time to
peak plasma concentration and tamper-resistant fea-
tures make the formulations less desirable for abuse
compared with IR formulations [9–11].
Transdermal buprenorphine (TDB) patches (marketed
under different names depending on the country: Norspan®,
Sovenor®, Butrans®, or Restiva®), in three dose strengths:
5 μg/h, 10 μg/h, or 20 μg/h, have been developed [12]. It is
licensed for the treatment of moderate to severe chronic
pain that do not respond to non-opioid analgesics [13–15].
Its active ingredient, buprenorphine, is a potent opioid
analgesic that acts primarily as a partial agonist at the μ-
opioid receptor [16]. TDB offers several advantages over
typical full μ-opioid receptor agonists in treating chronic
pain. First, its unique partial agonist activity induces a ceil-
ing effect for respiratory depression but not for analgesia,
resulting in a reduced risk for this potentially fatal adverse
event compared to other full opioid agonists [17, 18]. Next,
TDB has a lower propensity for opioid abuse or addiction
than typical full opioid agonists [9, 17] and its transdermal
matrix makes it difficult to extract the substance for non-
medical use [10]. In addition, unlike most full opioid
agonists which are eliminated primarily in urine, buprenor-
phine is mainly excreted through the feces and does not
accumulate in the body. This makes it more suitable and
convenient to use than full opioid agonists because it does
not require special dose adjustments in patients with
compromised renal function, such as the elderly or renal
patients [18–21]. Next, TDB releases a steady and continu-
ous dose of buprenorphine over a period of up to seven
days which confers the convenience of once-weekly dosing.
Given that prescribing of analgesics in patients with muscu-
loskeletal disorders may be complicated by comorbid con-
ditions and polypharmacy, the extended analgesia duration
offered by TDB allows for less frequent dosing and reduces
pill burden compared with other oral opioid agonists. This
may help improve patient acceptability and adherence.
Besides these, TDB can be used by patients who have
difficulty swallowing, or have gastrointestinal disorders, or
preexisting nausea and vomiting and are unable to take oral
opioid analgesics [22].
TDB has demonstrated good efficacy and an acceptable
tolerability profile in patients with chronic non-malignant
pain in randomized controlled trials [23–25]. Pain inten-
sity and sleep disturbance were considerably reduced and
patients experienced improved physical function and
quality of life after treatment. TDB was tolerated by the
majority of the patients in these studies [23–25]. TDB was
noted to be non-inferior to other opioid analgesics in
reducing pain. Apart from application site reactions that
were typical of transdermal delivery systems, TDB has an
AE profile that is comparable with the other opioid
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analgesics [23, 25]. However, real-world data on treatment
of chronic pain with TDB is limited [26]. To date, there
are no multinational studies examining the use of TDB in
Asian patients with chronic non-malignant pain. This
study aimed to assess the effectiveness and tolerability of
TDB in real-life clinical settings in Asian patients who
were suffering from moderate to severe musculoskeletal
pain.
Methods
Study design
This was a prospective, multicenter, open-label, single-
arm study conducted in 16 hospital sites across three
countries or territories in Asia (Hong Kong, Korea, and
the Philippines) between June 2013 and April 2015. The
study comprised a screening and baseline visit (visit 1)
to assess patient eligibility and collect baseline data,
followed by a titration period of up to six weeks, during
which patients received the study medication and their
dose was adjusted as necessary to achieve optimal pain
control. Patients then entered an 11-week treatment
period and attended a follow-up visit two weeks after
completion of treatment. The study consisted of at least
seven scheduled visits at specified intervals (Fig. 1).
Patients
Inclusion criteria were as follows: (i) 18–80 years of age;
(ii) clinical diagnosis of osteoarthritis, rheumatoid arth-
ritis, low back pain, or joint/muscle pain; and (iii) chronic
moderate to severe pain [defined as a score of ≥4 on the
Box Scale-11 (BS-11) pain scale], not adequately con-
trolled with non-opioid analgesics and requiring an opioid
for adequate analgesia. Exclusion criteria included the
following: (i) pregnant or lactating females; (ii) females of
childbearing potential who were not willing to use appro-
priate contraception during the study; (iii) current diag-
nosis or history of cancer (except basal cell carcinoma);
(iv) previous surgery or required surgery; (v) history of
alcohol or drug abuse, or behaviors suggestive of addic-
tion or substance abuse; (vi) presence of any contraindica-
tion to the study medication; (vii) other chronic conditions
that required frequent analgesic therapy; (viii) history of
allergy to analgesic agents; (ix) history of prior treatment
with study medication; (x) history of opioid treatment; (xi)
current or history of steroid treatment; and (xii) deemed
unsuitable for participation by the study physician.
Study treatment
7-day TDB patches, available in three dose strengths:
5 μg/h, 10 μg/h, and 20 μg/h, were used in this study.
Patients started with a 5 μg/h buprenorphine patch at
the baseline visit and were titrated as necessary to a
maximum of 40 μg/h over a 6-week period to achieve
optimal pain relief. Dose titration and patch application
were carried out according to the instructions stated in
the local summary of product characteristics or patient
information leaflet [13–15]. Patients were prescribed
standard recommended doses of rescue analgesics as
needed. Antiemetics and laxatives were also permitted, if
required. The optimal buprenorphine dose was deter-
mined at the physician’s discretion based on patient’s
need for supplemental pain relief and analgesic response
to the patch. Patients wore the patch continuously for
7 days before titration to the next dose was considered;
Follow up
(2 weeks)
Screening 
cum Initiation
Titrate 
buprenorphine 
dose up to 
max. 40 µg/h
Continue treatment with 
titrated buprenorphine dose 
V1 V2 (V2†) V3            V4              V5              V6* V7
Titration (1 to 6 weeks) Treatment (11 weeks)
Informed 
consent
Initiate 
Buprenorphine 
5 µg/h
Visit schedule: V2/V2† (V1 + up to 6 weeks); V3 (1 week 3 days after V2); V4 (2 weeks 3 
days after V3); V5 (4 weeks 3 days after V4); V6 (4 weeks 3 days after V5); V7 (2 weeks 
3 days after V6)
V2†: Subsequent optional titration visits
*Patients could choose to continue on transdermal buprenorphine treatment, subjected to their 
physicians’ approval.
Fig. 1 Study design
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however, the dose could be increased earlier, after three
days of application if patients did not experience ad-
equate analgesia despite administration of rescue analge-
sics. Buprenorphine dose was increased gradually in
increments of 5 μg/h either with a patch of higher dose
strength or with a combination of patches. No more
than two patches were applied at the same time and a
new skin site was selected for application. Patients who
achieved optimal pain control entered the treatment
period, which lasted for 11 weeks. During this period,
the physicians adjusted patients’ doses as necessary to
maintain optimal pain control. Patients stopped TDB
treatment when they completed the 11-week treatment.
However, they could choose to continue on TDB treat-
ment, subjected to their physicians’ approval.
Study assessments
Patients’ demographics and disease characteristics were
collected at visit 1. Information relating to concomitant
illness was collected throughout the study. Concomitant
illness was defined as any medical condition, other than
the primary condition, that occurred within the last five
years prior to study entry or during the course of the
study.
Primary efficacy assessment
The primary efficacy assessment was the BS-11 pain
score. Before the start of treatment (visit 1) and at each
subsequent visit, patients rated their pain level on the
BS-11 scale, ranging from a scale of 0 (no pain) to 10
(unbearable pain) [27].
Secondary efficacy assessments
The secondary efficacy assessments were as follows:
1. Global Sleep Quality Assessment Scale (GSQA)
Before treatment (visit1) and at the end of treatment
(visit 6) and the follow-up visit (visit 7), patients
evaluated their overall sleep quality, degree of sleep
disturbance, and sleep duration using the 8-item
GSQA scale questionnaire. The GSQA scale ranges
from 0 to 10, with higher scores indicating a higher
degree of sleep disturbance.
2. EuroQol Group 5-Dimension Self-Report
Questionnaire-3 Level Version Survey (EQ-5D-3 L
questionnaire)
Patients assessed their quality of life using the EQ-5D-
3 L questionnaire at visits 1, 6, and 7. The question-
naire includes the EQ-5D visual analogue scale (EQ
VAS) where patients rated their overall health state
on a scale ranging from 0 (worst imaginable health
state) to 100 (best imaginable health state). It also
includes the descriptive system comprising the
following five dimensions: mobility, self-care, usual
activities, pain or discomfort, and anxiety or
depression where patients indicated their levels
of functioning at one of the three levels: no problems,
some problems, and extreme problems [28].
3. Global Impression of Change Assessment
Both patients and physicians evaluated the change
in overall pain condition since the initiation of
treatment. They completed the Patient Global
Impression of Change questionnaire [29] and the
Physician Global Impression of Change questionnaire
[30], respectively at visit 6. The change was rated
on a 7-point scale. A score of 1 indicates “very much
improved”, 2 “much improved”, 3 “minimally
improved”, 4 “no change”, 5 “minimally worse”,
6 “much worse”, and 7 “very much worse”.
4. Concomitant rescue medication use
Patients recorded their rescue medication intake in
the patient diary throughout the study.
Local language version of all questionnaires was used
in each country or territory.
Safety assessments
The physicians recorded all adverse events (AEs) that
occurred during the study. Vital signs measurements
and physical examination were performed at visits, 1, 6,
and 7.
Statistical analysis
Sample size estimation
The sample size was estimated based on the results of
previous studies [23–25]. Assuming a dropout rate of
20%, it was calculated that at least 53 patients had to be
recruited from each country to detect differences in
BS-11 scores from baseline for each country at 90%
statistical power and at the 5% significance level. As
recruiting was progressing more slowly than expected,
it was decided to evaluate the overall change in pain
scores for the combined study population to ensure
sufficient power. Therefore, a total of 119 patients were
recruited from the participating countries.
Efficacy analysis
The primary efficacy endpoint was the change in BS-11
pain scores between baseline and each visit. A linear
mixed model-repeated measures analysis was performed
to estimate the least squares (LS) mean change in scores
from baseline and 95% confidence intervals (CIs).
Baseline score, visit, and country or territory were in-
cluded as covariates in the model.
Secondary endpoints evaluated included: (i) GSQA
overall sleep quality rating, sleep disturbance scores, and
sleep duration; (ii) EQ VAS score and ratings for individ-
ual EQ-5D-3 L dimensions; (iii) patients’ and physicians’
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Global Impression of Change scores; and (iv) prescribed
concomitant rescue medications. The Bowker-McNemar
test was used to compare patients’ ratings for their over-
all sleep quality and individual ED-5D-3 L dimensions
between visits. Parametric tests were performed where
assumptions of normality were met. Otherwise, nonpara-
metric tests were used. The Wilcoxon signed-rank test
was used to compare patients’ GSQA sleep disturbance
scores and sleep duration between visits, and to compare
patients’ and physicians’ Global Impression of Change
scores. The paired t-test was used to compare EQ VAS
scores between visits. Rescue medication use was sum-
marized using descriptive statistics.
The intent-to-treat (ITT) population was the primary
population for efficacy analysis. The efficacy data were
analyzed using the per-protocol (PP) population to pro-
vide confirmation. The ITT population included eligible
patients who received at least one dose of study medica-
tion and had pre- and at least one post-intervention as-
sessment of efficacy variables. The PP population was
defined as a subset of the ITT population who had com-
pleted all the visits without major protocol deviation or
violation. All analyses were conducted using available data;
no imputation was performed for missing data. A p-value
of less than 0.05 was considered as statistically significant.
Safety analysis
Key safety endpoints evaluated included the incidence of
treatment-emergent adverse events (TEAEs) and incidence
of TEAEs leading to discontinuation, as well as changes in
vital signs and physical examination parameters from
baseline to visits 6 and 7. A TEAE was defined as any
AE with an onset date on or after the first dose of TDB.
Medications prescribed for prevention or for treatment
of AEs associated with the study medication were also
evaluated. Safety results were descriptively summarized
for the safety population. The safety population in-
cluded eligible patients who received at least one dose
of study medication and had at least one safety follow
up. All statistical analyses were performed using SAS
software, version 9.3 (SAS Institute, Inc., USA).
Results
Patient demographics and baseline characteristics
The flow of patients through the study is shown in Fig.
2. One hundred and nineteen patients were enrolled into
the study, five of whom did not meet the eligibility
criteria and were excluded from the analysis. Among the
remaining one hundred and fourteen eligible patients
who received TDB treatment, 64 patients (56.1%) com-
pleted the study and 50 (43.9%) discontinued from the
study. The reasons for discontinuation are summarized
in Fig. 2. All 114 patients were included in the ITT
population and safety population. The PP population in-
cluded 63 patients who completed the study and had no
major protocol deviation or violation.
Patients’ demographics and characteristics at study entry
are summarized in Table 1. Fifty-four percent of patients
were from Korea while the rest were from Hong Kong
and the Philippines (22.8% each). The study population
ITT or safety population: 114
PP population: 63
Enrolled
n = 119
Eligible
n = 114
Violated eligibility
criteria
n = 5
Discontinued
n = 50
Adverse event: 33
Withdrawal of consent: 6
Lost to follow-up: 3
Non-compliance with protocol 3
Ineffective therapy: 3
Other: 2
Completed
n = 64
Fig. 2 Flow of patients through the study
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was predominantly female (75.4%), with a mean age of
57.0 (SD 13.4) years. Common causes of musculoskeletal
pain were osteoarthritis (48.3%) and low back pain
(37.7%). Sixty-two percent of patients had moderate pain
(BS-11 score 4 to 6) and 38.1% had severe pain (BS-11
score ≥ 7) at study entry. The majority of patients (81.6%)
reported at least one concomitant illness during the study
period. Patients’ demographics and characteristics varied
across the countries or territories. The Philippines tended
to have a higher mean age (62.2 [SD 11.3]) years and a
higher proportion of female patients (84.6%) than Hong
Kong and Korea. In Hong Kong, patients reported a fairly
even distribution of pain arising from a range of musculo-
skeletal conditions, with a trend towards higher frequency
of low back pain (34.6%). In Korea, low back pain (51.6%)
and osteoarthritis (46.8%) were more common while
osteoarthritis (76.9%) was the most common cause of
chronic pain in the Philippines. Hong Kong had the high-
est proportion of patients (96.2%) who had concomitant
illnesses across countries or territories.
Exposure
Patients received TDB for a median duration of 12.1
(range 0.3 to 19.1) weeks, at a median dose of 5.0 (5.0 to
40.0) μg/h over the study period. All patients were
initiated on TDB at a median dose of 5.0 μg/h. The dose
during titration was 5.0 (range 5.0 to 10.0) μg/h at visit 2
(n = 100) and was titrated to 10.0 (range 5.0 to 40.0) μg/h
among those who required additional titration (n = 67). It
decreased to 5.0 (range 5.0 to 40.0) μg/h at visit 3 and was
maintained at the same dose for the rest of the treatment
period (Fig. 3). The most frequently prescribed dose over
the study period was 5 μg/h (65.1% of total prescriptions),
followed by 10 μg/h (22.7%), and 15 μg/h (7.4%). Other
doses were less frequently used: 20 μg/h (2.5%), 25 μg/h
(1.0%), 30 μg/h (0.4%), and 40 μg/h (1.0%).
Efficacy
The results of all efficacy analyses conducted in the
ITT population were consistent with those of the PP
analyses. Therefore, only results of the ITT population
are presented here.
Change in BS-11 pain score
Figure 3 summarizes the change in BS-11 scores from
baseline to the end of study in the ITT population. The
mean BS-11 score at baseline was 6.2 (SD 1.6). Following
initiation of TDB treatment, there was a statistically sig-
nificant improvement in BS-11 score from baseline to visit
3, which was maintained till the end of the study (visit 7)
(p < 0.0001 for all). The corresponding LS mean change in
score from baseline was −2.27 (95% CI -2.66 to −1.87) at
visit 3 and −2.64 (95% -3.05 to −2.23) at visit 7.
Improvements in sleep quality and quality of life
A marginally significant improvement (p = 0.054) in
overall sleep quality assessment was observed at visit 6.
The proportion of patients rating sleep quality as ‘good’
increased from 14.0% at baseline to 26.9% at visit 6. Pa-
tients reported a median sleep duration of 6.0 (range 2.0
to 9.0) hours per night over the seven days prior to the
start of treatment. There was no clear improvement in
sleep duration from baseline at visit 6. Patients reported
minimal or low degree of sleep disturbance for all six
variables at baseline (Table 2). By visit 6, the median sleep
disturbance scores for the sleep variables “trouble falling
asleep” and “awakened by pain in the morning” improved
significantly by one unit from baseline (p < 0.0001 for
both). There were no clear improvements in scores for the
other sleep variables at visit 6 (Table 2).
The mean EQ VAS score at baseline was 59.6 (SD 15.9).
Patients’ overall health state improved significantly from
baseline (p < 0.0001) after treatment. By visit 6, the mean
EQ VAS score had increased by 7.7 units (SD 17.9). There
were also significant improvements in patients’ levels of
functioning for all EQ-5D-3 L dimensions from baseline
at visit 6 (p < 0.05 for all) (Fig. 4). The proportion of pa-
tients who indicated they had no problem with each
dimension increased from baseline to visit 6: mobility
(from 29.0% to 54.8%), self-care (from 60.5% to 80.7%),
usual activities (from 29.0% to 48.4%), pain or discomfort
(from 6.1% to 20.4%), anxiety or depression (from 36.8%
to 54.8%) (Fig. 4).
Table 1 Patient demographics and characteristics at study entry
Characteristics Safety population
Hong Kong
(n = 26)
Korea
(n = 62)
Philippines
(n = 26)
All
(n = 114)
Age (years), mean (SD) 55.2 (7.7) 55.6 (15.5) 62.2 (11.3) 57.0 (13.4)
Gender, n (%)
Male 8 (30.8) 16 (25.8) 4 (15.4) 28 (24.6)
Female 18 (69.2) 46 (74.2) 22 (84.6) 86 (75.4)
Causes of pain, n (%)
Osteoarthritis 6 (23.1) 29 (46.8) 20 (76.9) 55 (48.3)
Rheumatoid arthritis 6 (23.1) 0 (0.0) 2 (7.7) 8 (7.0)
Low back pain 9 (34.6) 32 (51.6) 2 (7.7) 43 (37.7)
Joint or muscle pain 5 (19.2) 1 (1.6) 2 (7.7) 8 (7.0)
aConcomitant illnesses, n (%)
Yes 25 (96.2) 48 (77.4) 20 (76.9) 93 (81.6)
No 1 (3.8) 14 (22.6) 6 (23.1) 21 (18.4)
SD standard deviation
aConcomitant illness was defined as any medical condition, other than the
primary condition, that occurred within the last five years prior to study entry
or during the course of the study
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*p <0.0001 Error bars represent 95% confidence intervals of the mean.
*
Baseline Visit 2 Visit 2† Visit 3 Visit 4 Visit 5 Visit 6 Visit 7
Mean (SD) BS-11 score 6.16 (1.57) 4.58 (2.19) 5.27 (2.02) 3.53 (1.68) 3.33 (1.76) 2.93 (1.95) 3.56 (2.42) 3.15 (2.35)
n 114 100 67 85 78 68 12 -
Median (range) dose
(µg/h)
5.0* 5.0
(5.0 to 10.0)
10.0
(5.0 to 40.0)
5.0
(5.0 to 40.0)
5.0
(5.0 to 40.0)
5.0
(5.0 to 40.0)
10.0
(5.0 to 40.0)
-
BS-11 Box Scale-11; LS least squares; SD standard deviation
*All patients started on 5 g/h of TDB
†Subsequent optional titration visits
Fig. 3 Change in BS-11 scores from baseline to visit 7 (ITT population)
Table 2 Improvements in GSQA scores from baseline to visit 6
GSQA Variables ITT population (n = 114)
Trouble falling
asleep
Need pain medication
to sleep
Need sleep medication
to sleep
Awakened by
pain at night
Awakened by pain
in the morning
Effect of pain on
partner’s sleep
Baseline n 114 114 114 114 114 86
Median
(range)
3.00 (0.00 to 10.00) 1.00 (0.00 to 10.00) 0.00 (0.00 to 10.00) 2.00 (0.00 to 10.00) 2.00 (0.00 to 10.00 1.00 (0.00 to 10.00)
Mean (SD) 3.73 (3.18) 2.30 (2.96) 0.91 (2.13) 3.09 (3.19) 2.96 (3.41) 2.71 (3.42)
Missing 0 0 0 0 0 28
Visit 6 n 93 93 93 93 93 80
Median
(range)
1.00 (0.00 to 10.00) 0.00 (0.00 to 10.00) 0.00 (0.00 to 10.00) 1.00 (0.00 to 10.00 2.00 (0.00 to 10.00 0.00 (0.00 to 10.00
Mean (SD) 2.34 (2.85) 1.74 (2.86) 0.91 (2.13) 2.30 (2.89) 2.96 (3.41) 1.69 (2.60)
Missing 21 21 21 21 21 34
aChange n 93 93 93 93 93 70
†p-value <0.0001 0.001 0.578 0.004 <0.0001 0.007
Median
(range)
−1.00 (−10.00 to 5.00) 0.00 (−10.00 to 7.00) 0.00 (−10.00 to 10.00) 0.00 (−10.00 to 7.00) −1.00 (−10.00 to 7.00) 0.00 (−10.00 to 5.00)
Mean (SD) −1.68 (3.15) −0.86 (2.83) −0.14 (2.85) −1.04 (3.28) −1.53 (3.27) −1.09 (3.08)
Missing 21 21 21 21 21 44
GSQA Global Sleep Quality Assessment Scale, ITT intent-to-treat, SD standard deviation
aOnly patients with non-missing data at both visits 1 and 6 are included in the calculation for the change in scores from visit 1
†Wilcoxon signed-rank test
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Patient and physician global assessment of pain relief
There was no significant difference between patients’
and physicians’ Global Impression of Change scores at
visit 6 (p = 0.248). The median Global Impression of
Change score was 3.0 (range 1.0 to 5.0) for both patients
and physicians, indicating perceived improvement in
overall pain condition at the end of TDB treatment.
Rescue medication use
Only 22.8% of patients required rescue medications during
the study period. The most frequently prescribed rescue
medications were acetaminophen (56.1% of total prescrip-
tions), followed by diclofenac (23.6%). Other medications
were less frequently used (0.8–7.3%).
Safety
Overall, eighty-nine patients (78.1%) reported TEAEs,
most of which were mild to moderate in intensity (96.5%).
The most common TEAEs reported during the study were
nausea (39.5%) and constipation (31.6%), followed by
dizziness (27.2%), somnolence (19.3%), vomiting (16.7%),
headache (8.8%), pruritus (7.9%), and -application site
reactions (6.1%). Sixty-eight percent of patients had
TEAEs that were assessed to be related to the study medi-
cation by the physician. One serious TEAE was reported
during the course of the study. A patient experienced a
hypertensive crisis; the event was moderate in severity but
was not considered related to the study medication. The
incidence of TEAEs leading to discontinuation was 22.8%,
most of the events were mild-moderate in intensity
(92.9%). TEAEs that frequently led to discontinuation of
the study medication included nausea (11.4%), dizziness
(7.9%), and vomiting (5.3%).
Table 3 summarizes the incidence of TEAEs and
common TEAEs, as well as the practice pattern in AE
management of TDB treatment in the participating
countries or territories. The incidence of TEAEs varied
across countries or territories: Korea had a lower inci-
dence of TEAEs (69.4%) than the Philippines (80.8%)
and Hong Kong (96.2%). A similar trend was also ob-
served for discontinuation due to TEAEs, with a lower
incidence in Korea (14.5%) than the Philippines (26.9%)
and Hong Kong (38.5%). Physicians more frequently
prescribed medications to treat AEs that occurred during
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Fig. 4 Comparison of patients’ levels of functioning for individual EQ-5D-3 L dimensions between baseline and visit 6 (ITT population)
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TDB treatment than to manage them prophylactically
(Table 3). Only 14.9% of patients received prophylactic
medications while 23.7% received medications for treat-
ment of AEs. Antiemetics were the most common pre-
emptive treatment prescribed while both antiemetics and
laxatives were commonly prescribed to treat AEs. Of note,
physicians in Korea, the country with the lowest incidence
of TEAEs, tended to prescribe medications both to pre-
vent (24.2%) and treat (22.6%) AEs. In contrast, physicians
in the Philippines and Hong Kong tended to prescribe
medications to treat AEs (19.2% and 30.8%, respectively)
rather than to prevent their occurrence (0.0% and 7.7%,
respectively) (Table 3).
There were no clinically significant changes in vital
signs or physical examination results between baseline
and the end of the study.
Discussion
This is the first multinational study of TDB treatment
in Asian patients who were suffering from moderate to
severe pain due to a range of musculoskeletal condi-
tions. This study, reflecting real-world clinical practice,
demonstrates that TDB provides effective pain relief
and improves daily functioning and quality of life in
Asian patients with chronic musculoskeletal pain after
11 weeks of treatment. Additionally, TDB demonstrates
an acceptable tolerability profile in our Asian cohort over
the treatment period, consistent with that observed in
Caucasians.
In the present study, patients entered the study with an
average BS-11 pain score of 6.2. After initiation of TDB,
the mean BS-11 score decreased by 2.3 unit one week
after the end of the titration period and the reduction was
maintained till the end of the treatment period (LS mean
change: −2.5 at visit 6). A reduction of approximately
2 units from baseline on the 11-point numeric rating scale
has been demonstrated to correspond to a clinically mean-
ingful improvement [31]. The improvements in BS-11
score observed in this study are therefore considered
clinically relevant. In addition, the majority of patients did
not require additional rescue medications for pain. Similar
improvements were observed in an open-label, random-
ized trial conducted in UK [23]. In this trial, reduction in
BS-11 score was sustained over the 11-week treatment
period (mean reduction: 3.6 at end of titration and 4.0 at
week 12) in patients with knee and/or hip osteoarthritis
who received TDB plus oral paracetamol [23]. The ben-
efits of TDB in providing analgesia in patients with
chronic moderate to severe non-malignant pain are
supported by results from other studies [25, 26]. In a
prospective study of younger patients and elderly patients
with osteoarthritis-related pain in Sweden, Karlsson et al.
observed significant reductions in BS-11 score in patients
who were treated with TDB, regardless of age (LS mean
change: −1.9 to −2.2). In addition, patients used less res-
cue medications after the start of the 12-week treatment.
The mean number of tablets of rescue medication taken
each day reduced from 5.2 to 5.7 at baseline to 2.1 to 2.8
during the treatment period [26]. In another open-label,
randomized study comparing the efficacy and safety of
TDB with prolonged-release tramadol tablets, similar
improvement in BS-11 score (LS mean change: −2.3) was
reported in Swedish patients after 12 weeks of treatment
with TDB [25].
Significant differences in the metabolism and response to
medicines have been documented among racial groups
[32]. The prescribed TDB dose was lower in this study
compared to other studies conducted in Caucasian patients
[24, 26, 33]. The median dose for the last dose prescribed
during the treatment period in this study was 5 μg/h while
higher doses (10–24 μg/h) were prescribed in other studies
Table 3 Incidence of TEAEs and common TEAEs, and AE
management of TDB treatment
Safety population
Hong Kong
(n = 26)
n (%)
Korea
(n = 62)
n (%)
Philippines
(n = 26)
n (%)
All
(n = 114)
n (%)
Incidence of TEAEs 25 (96.2) 43 (69.4) 21 (80.8) 89 (78.1)
TEAEs leading to
discontinuation
10 (38.5) 9 (14.5) 7 (26.9) 26 (22.8)
aCommon TEAEs
Nausea 11 (42.3) 27 (43.6) 7 (26.9) 45 (39.5)
Constipation 10 (38.5) 20 (32.3) 6 (23.1) 36 (31.6)
Dizziness 13 (50.0) 9 (14.5) 9 (34.6) 31 (27.2)
Somnolence 9 (34.6) 8 (12.9) 5 (19.2) 22 (19.3)
Vomiting 9 (34.6) 4 (6.5) 6 (23.1) 19 (16.7)
Headache 4 (15.4) 2 (3.2) 4 (15.4) 10 (8.8)
Pruritus 4 (15.4) 4 (6.5) 1 (3.9) 9 (7.9)
Application site
reactions
3 (11.5) 0 (0.0) 4 (15.4) 7 (6.1)
bAE management of TDB treatment
Received medications
for prevention and/or
treatment of common
AEs
10 (38.5) 26 (41.9) 5 (19.2) 41 (36.0)
cPrevention 2 (7.7) 15 (24.2) 0 (0.0) 17 (14.9)
Antiemetics 1 (3.9) 15 (24.2) 0 (0.0) 16 (14.0)
Laxatives 1 (3.9) 0 (0.0) 0 (0.0) 1 (0.88)
dTreatment 8 (30.8) 14 (22.6) 5 (19.2) 27 (23.7)
Antiemetics 2 (7.7) 11 (17.7) 2 (7.7) 15 (13.2)
Laxatives 5 (19.2) 3 (4.8) 5 (19.2) 13 (11.4)
Antivertigo agents 3 (11.5) 0 (0.0) 0 (0.0) 3 (2.6)
AE adverse event, TDB transdermal buprenorphine, TEAE treatment-emergent
adverse events
aOccurring in ≥5% of the overall safety population
bPatients may receive one or more medications for AE management
cPrescribed on the same date as the start date of TDB treatment
dPrescribed after the start of TDB treatment
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[24, 26, 33]. This findings suggest that Asian patients may
require lower doses of TDB than Caucasian patients. More
studies are needed to establish the dose level of TDB for
treatment of pain in Asian patients.
The goal of chronic pain management encompasses not
only the relief of pain, but also maintaining or improving
the daily functioning and quality of life of patients [2]. In
the present study, in addition to reduction of pain inten-
sity, patients’ quality of life and levels of functioning im-
proved at the end of treatment with TDB. The proportion
of patients who rated sleep quality as ‘good’ on the 8-item
GSQA scale increased after treatment. Patients reported
improvement in overall health state (EQ VAS) after treat-
ment. Improvements in patients’ levels of functioning for
all dimensions of the EQ-5D-3 L questionnaire were also
observed. Similar results were observed in previous
studies of TDB [25, 26]. In the study by Karlsson et al.,
patients reported fewer nights of sleep disturbance. The
EQ VAS score increased by an average of 6.8 at study
completion [26]. In another study, the majority of patients
(71%) reported improved ratings in sleep quality at the
end of treatment. Improvement in EQ VAS score at study
completion was also observed [25].
Consistent with the decrease in pain scores in the
present study, both physicians and patients rated TDB
treatment as associated with improvement in the over-
all pain condition. Previous studies of TDB have also
reported favorable physician and patient ratings for
TDB treatment [25, 26]. In the recent study by Karlsson
et al., the majority of physicians (61 to 65%) and patients
(59 to 68%) rated TDB as “good” or “very good” at
relieving pain [26]. Similar high proportions were
reported in another study (physicians: 72.1%, patients:
64.7%, respectively) [25].
No unexpected safety or tolerability concerns were
raised in the present study. Although the incidence of AEs
and the incidence of discontinuations due to AEs were
high, these were not unexpected as the incidence rates
were consistent with those reported in previous studies of
TDB conducted in Caucasian patients (incidence of AEs:
86 to 91% and incidence of discontinuations: 15 to 35%)
[23–26]. As with previous studies, AEs were generally
mild or moderate. The most common AEs reported were
consistent with the AE profile of TDB in general [23–26].
Of note, the incidence of skin reactions reported in this
study was lower than that reported in other studies (27 to
30%) [23, 24]. As with previous studies [23, 25, 26], no
significant abnormalities in vital signs or physical examin-
ation parameters were reported during the study.
Clinical guidelines from the American Pain Society-
American Academy of Pain Medicine and the European
Association for Palliative Care (EAPC) recommend physi-
cians to employ preemptive intervention or symptomatic
management of AEs to minimize the common side effects
of opioid therapy [34, 35]. In the present study, pre-
scription of medications for prevention or treatment of
common AEs of TDB treatment was uncommon
despite the high incidence of AEs reported. Although
guidelines recommend to routinely prescribe laxative
for prophylaxis management of opioid-induced consti-
pation [34, 35], prescription of prophylactic laxative
treatment was low in this study. These findings indicate
a significant gap between guideline recommendations
and the actual practice in managing the side effects of
opioid treatment in the participating countries or territor-
ies. The development of education and training strategies
to improve physicians’ knowledge and to raise their aware-
ness on opioid treatment may lead to improvements in
treatment adherence.
In the present study, the incidence of AEs and the
incidence of discontinuations varied across the countries
or territories. The incidence rates appeared consistent
with the practice pattern in side effect management of
TDB treatment in each country or territory. Lower inci-
dence rates were observed in Korea where medications
for management of common AEs were prescribed both
prophylactically and after TDB treatment. In contrast,
higher incidence rates were observed in Hong Kong and
the Philippines where physicians tended to prescribe
medications to treat AE rather than to prevent their oc-
currence. These findings highlight the importance of pre-
emptive and active management of side effects of TDB
treatment in supporting treatment adherence. While
practice pattern in side effect management influence the
incidence rates, it is possible that ethnic differences in the
development of AEs may exist. More studies are needed
to confirm if the varying AE profile across the countries
or territories is due to ethnic differences. This will provide
valuable information for physicians to properly manage
the use of TDB for pain management in different ethnic
groups.
Our findings need to be interpreted within the limita-
tions of the study. First, the treatment duration of 11 weeks
is relatively short, and whether the observed treatment
effect continues in the longer term would require further
research to confirm. Next, the GSQA questionnaire has
not been formally validated. Nevertheless the use of a
structured questionnaire to assess sleep disturbance and
sleep quality ensured consistency in data collection before
and after TDB treatment and minimized bias to some
extent. Another limitation is that the study population
comprised a heterogeneous mix of musculoskeletal condi-
tions with distinct pathophysiological mechanisms. It is
probable that some conditions responded better than
others to the treatment. However, the sample size is too
small to allow parsing of the results by musculoskeletal
condition. Future studies in additional populations of pa-
tients are needed to evaluate the effect of TDB in different
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conditions. In addition, there is potential for bias due to
the open-label study design and the lack of active control
in this study which preclude evaluation of the extent to
which the observed effect is caused by the treatment.
Nonetheless, the present study closely reflects the real-life
clinical setting and the results are more likely to translate
effectively into real-world clinical practice.
Conclusions
Our study provides real-world clinical evidence on the
effectiveness and tolerability of TDB in Asian patients
with moderate to severe chronic pain. Treatment with
TDB resulted in effective and sustained pain relief over
the 11-week treatment period, accompanied by im-
provements in daily functioning and quality of life. The
tolerability profile was as expected as previous studies
of TDB. Our results indicate that TDB can be consid-
ered a suitable alternative treatment option to control
non-malignant musculoskeletal pain. Studies on the
long-term efficacy and safety of TDB treatment are re-
quired to further confirm these findings.
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